In the aspect of Weiming medicine, it is still the pattern of individual investors game. Among the total 10 seats on the dragon and tiger list, the Lhasa Business Department of Oriental Fortune occupies six seats, and there is no more common hot money seat. On the evening of October 19, Weiming pharmaceutical said in its reply letter that Beijing Kexing, a joint-stock company, had not yet received an effective reply from Beijing Kexing on its participation in the Sino Uygur cooperative development and development of new crown vaccine.
According to a number of media reports, Zhejiang has uniformly ordered a new crown vaccine from Kexing Zhongwei. There is still no clear official statement on whether Beijing Kexing will participate in vaccine production. 1globe, a major shareholder in the US stock company, recently accepted the settlement proposal proposed by the US SEC in an attempt to promote the resumption of the company. Due to the long-standing dispute over the control right of Kexing biological, its trading was suspended for a long time, which missed the opportunity of performance in the capital market.
A large private placement official in Shenzhen told the interface news reporter that he believed that excessive hype in the vaccine plate was the main reason for the recent decline, and it was relatively cautious to study and judge the future performance.
According to the analysis of institutional investors, the general rising market of the vaccine sector is coming to an end. From the perspective of R & D progress, only a few listed companies such as kangxinuo are expected to benefit from the launch of Xinguan vaccine. The time point for institutional funds to group together to defend the vaccine plate has passed. From the perspective of recent market performance, hot money is dumping chips to retail investors in the final stage of speculation, even though the market is still in its final stage The recent rebound in the vaccine plate, has also reached the fish tail stage of the market.